Mayne Pharma Group (ASX:MYX) EPS (Basic): A$-1.06 (TTM As of Dec. 2025)


ASX:MYX Mayne Pharma Group Ltd ASX:MYX
51 GF Score
Price A$2.57
GF Value A$5.31
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group EPS (Basic)?

Mayne Pharma Group ASX:MYX +7.53% 51 EPS (Basic) is A$-1.06 as of Dec. 2025. GuruFocus rates ASX:MYX with a GF Score™ of 51/100 and a GF Value™ of A$5.31 (Possible Value Trap). The stock has 3 warning signs investors should review.

Mayne Pharma Group's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was A$-0.18. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.06.

Mayne Pharma Group's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.06.

Mayne Pharma Group's EPS without NRI for the six months ended in Dec. 2025 was A$-0.13. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -1.02.

During the past 3 years, the average EPS without NRI Growth Rate was 9.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -54.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Mayne Pharma Group's highest 3-Year average EPS without NRI Growth Rate was 30.80% per year. The lowest was -139.00% per year. And the median was -12.20% per year.

Mayne Pharma Group  (ASX:MYX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Mayne Pharma Group EPS (Basic) Related Terms

Mayne Pharma Group EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group EPS (Basic) Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.65 -3.20 1.42 -2.12 -1.19

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -1.24 -0.31 -0.88 -0.18
ASX:MYX
51GF Score
Mayne Pharma Group Ltd ASX:MYX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Mayne Pharma Group's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-93.836-0)/79.139
=-1.19

Mayne Pharma Group's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-14.939-0)/81.246
=-0.18

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of A$-1.06 mean?
Mayne Pharma Group (ASX:MYX) has a EPS (Basic) of A$-1.06 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Mayne Pharma Group and its competitors.
Is Mayne Pharma Group's EPS (Basic) too high?
Mayne Pharma Group's current EPS (Basic) is A$-1.06. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's EPS (Basic) compare to MCK and COR?
Mayne Pharma Group's EPS (Basic) of A$-1.06 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Distribution company?
A good EPS (Basic) depends on the Medical Distribution industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Mayne Pharma Group and its competitors. Mayne Pharma Group's current EPS (Basic) is A$-1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current EPS (Basic) is A$-1.06. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current EPS (Basic) is A$-1.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for ASX:MYX:

  • EPS (Basic): A$-1.06
  • GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MAYNF:USA
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score

Get the complete analysis for ASX:MYX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.57
Price
A$5.31
GF Value